|
Malignant neoplasm of breast
|
|
0.040 |
GeneticVariation
|
BEFREE |
SHMT C1420T mutations may reduce breast cancer susceptibility, whereas MTRR A66G and MS A2756G mutations may increase breast cancer susceptibility.
|
27347936 |
2016 |
|
Breast Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
SHMT C1420T mutations may reduce breast cancer susceptibility, whereas MTRR A66G and MS A2756G mutations may increase breast cancer susceptibility.
|
27347936 |
2016 |
|
Breast Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
Conversely, for women over 50, the risk of breast cancer development was statistically associated with the MTHFR 677CT genotype, but especially significant was risk associated with the presence of the polymorphic allele of cSHMT C1420T (P = 0.0120) and the protective effect associated with the RFC1 G80A polymorphism allele (P = 0.0021), was restrict to this age group.
|
22134752 |
2012 |
|
Breast Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
MTRR A66G and cSHMT C1420T polymorphisms influence CIMP phenotype of BNIP3, thus epigenetically regulating BNIP3 in breast cancer.
|
21987236 |
2012 |
|
Malignant neoplasm of breast
|
|
0.040 |
GeneticVariation
|
BEFREE |
Conversely, for women over 50, the risk of breast cancer development was statistically associated with the MTHFR 677CT genotype, but especially significant was risk associated with the presence of the polymorphic allele of cSHMT C1420T (P = 0.0120) and the protective effect associated with the RFC1 G80A polymorphism allele (P = 0.0021), was restrict to this age group.
|
22134752 |
2012 |
|
Malignant neoplasm of breast
|
|
0.040 |
GeneticVariation
|
BEFREE |
MTRR A66G and cSHMT C1420T polymorphisms influence CIMP phenotype of BNIP3, thus epigenetically regulating BNIP3 in breast cancer.
|
21987236 |
2012 |
|
Malignant neoplasm of breast
|
|
0.040 |
GeneticVariation
|
BEFREE |
Support of our hypothesis came from the following observations: (i) Allelic frequency of cSHMT C1420T was higher in the controls than in the cases, manifesting a 0.56-fold risk reduction in breast cancer (95%CI = 0.39-0.80); and this association was more significant in those women are susceptible to time of estrogen exposure.
|
17896178 |
2008 |
|
Breast Carcinoma
|
|
0.040 |
GeneticVariation
|
BEFREE |
Support of our hypothesis came from the following observations: (i) Allelic frequency of cSHMT C1420T was higher in the controls than in the cases, manifesting a 0.56-fold risk reduction in breast cancer (95%CI = 0.39-0.80); and this association was more significant in those women are susceptible to time of estrogen exposure.
|
17896178 |
2008 |
|
Prostate carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
In a meta-analysis of folate-pathway polymorphisms, MTR 2756A > G (eight studies, OR = 1.06; 95% CI 1.00, 1.12; P = 0.06) and SHMT1 1420C > T (two studies, OR = 1.11; 95% CI 1.00, 1.22; P = 0.05) were positively associated with prostate cancer risk.
|
23724740 |
2013 |
|
Colorectal Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Results for other variants varied across individual studies; in our meta-analyses we observed some evidence for SHMT 1420C>T (rs1979277) ((odds ratio) OR = 0.85; 95% confidence interval (CI) = 0.73-1.00 for TT v. CC) and TYMS 5' 28 bp repeat (rs34743033) and CRC risk (OR = 0.84; 95% CI = 0.75-0.94 for 2R/3R v. 3R/3R and OR = 0.82; 95% CI = 0.69-0.98 for 2R/2R v. 3R/3R).
|
23401104 |
2013 |
|
Malignant neoplasm of prostate
|
|
0.020 |
GeneticVariation
|
BEFREE |
In a meta-analysis of folate-pathway polymorphisms, MTR 2756A > G (eight studies, OR = 1.06; 95% CI 1.00, 1.12; P = 0.06) and SHMT1 1420C > T (two studies, OR = 1.11; 95% CI 1.00, 1.22; P = 0.05) were positively associated with prostate cancer risk.
|
23724740 |
2013 |
|
Adult Acute Lymphocytic Leukemia
|
|
0.020 |
GeneticVariation
|
BEFREE |
Children with ALL (n = 96) were screened for GCPII C1561T, RFC1 G80A, cSHMT C1420T, TYMS 5´-UTR 2R3R, TYMS 3´-UTR ins6/del6, MTHFR C677T, MTR A2756G polymorphisms using PCR-RFLP and PCR-amplified fragment length polymorphism techniques.
|
22838948 |
2012 |
|
Prostate carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Vitamin B(12), holo-haptocorrin, and the folate-pathway single-nucleotide polymorphisms MTR 2756A>G and SHMT1 1420C>T have been associated with an increased risk of prostate cancer.
|
20852008 |
2010 |
|
Malignant neoplasm of prostate
|
|
0.020 |
GeneticVariation
|
BEFREE |
Vitamin B(12), holo-haptocorrin, and the folate-pathway single-nucleotide polymorphisms MTR 2756A>G and SHMT1 1420C>T have been associated with an increased risk of prostate cancer.
|
20852008 |
2010 |
|
Colorectal Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Similarly, homozygosity for the C1420T SHMT polymorphism also had a 2.6-fold increased risk (95% CI: 1.1, 5.9) of developing CRC.
|
18996879 |
2008 |
|
Adult Acute Lymphocytic Leukemia
|
|
0.020 |
GeneticVariation
|
BEFREE |
Polymorphisms in methionine synthase (MS A2756G), cytosolic serine hydroxymethyltransferase (SHMT1 C1420T), and a double (2R2R) or triple (3R3R) 28-bp tandem repeat in the promoter region of thymidylate synthase (TS) were studied and found to modulate ALL risk.
|
11986237 |
2002 |
|
Hyperhomocysteinemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
To conclude, PD cases exhibited hyperhomocysteinemia and MTRR 66 A>G and cSHMT 1420 C>T gene variants were shown to modulate PD risk by altering the homocysteine levels.
|
24686188 |
2014 |
|
Acute lymphocytic leukemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
Children with ALL (n = 96) were screened for GCPII C1561T, RFC1 G80A, cSHMT C1420T, TYMS 5´-UTR 2R3R, TYMS 3´-UTR ins6/del6, MTHFR C677T, MTR A2756G polymorphisms using PCR-RFLP and PCR-amplified fragment length polymorphism techniques.
|
22838948 |
2012 |
|
Squamous cell carcinoma of the head and neck
|
|
0.010 |
GeneticVariation
|
BEFREE |
We conducted a case-control study (265 HNSCC cases and 466 non-cancer controls) to investigate associations of MTHFR C677T and A1298C, MTR A2756G, MTRR A66G, RFC1 A80G, MTHFD1 G1958A, CBS 844ins68, TC2 C776G and A67G, SHMT C1420T and BHMT G742A polymorphisms with HNSCC risk.
|
22051736 |
2012 |
|
Childhood Acute Lymphoblastic Leukemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
Children with ALL (n = 96) were screened for GCPII C1561T, RFC1 G80A, cSHMT C1420T, TYMS 5´-UTR 2R3R, TYMS 3´-UTR ins6/del6, MTHFR C677T, MTR A2756G polymorphisms using PCR-RFLP and PCR-amplified fragment length polymorphism techniques.
|
22838948 |
2012 |
|
Autistic Disorder
|
|
0.010 |
GeneticVariation
|
BEFREE |
MTHFR C677T is a risk factor, whereas MTRR A66G and SHMT C1420T polymorphisms reduce risk for autism.
|
19440165 |
2009 |
|
Lymphoma, Non-Hodgkin
|
|
0.010 |
GeneticVariation
|
BEFREE |
The polymorphisms examined and haplotypes generated included thymidylate synthase (TYMS 28-bp triple repeat [3R]-->double repeat [2R], 1494del6, IVS6 -68C>T, 1122A>G, and 1053C>T); 5,10-methylenetetrahydrofolate reductase (MTHFR 677C>T and 1298A>C); serine hydroxymethyltransferase (SHMT1 C1420T); reduced folate carrier (RFC G80A); and methionine synthase (MTR A2756G), making the present study the largest and most comprehensive to date to evaluate associations between genetic polymorphisms in folatemetabolizing genes and NHL risk.
|
15198953 |
2004 |